RVLPQ OTC
RVL Pharmaceuticals plc
1W: +900.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: +0.0%
3Y: -100.0%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$3.1M
52W Range0.000001-0.0005
Volume600
Avg Volume9,532
Beta8.80
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOBrian A. Markison
Employees125
SectorHealthcare
IndustryBiotechnology
IPO Date2018-10-18
Websitervlpharma.com
400 Crossing Boulevard
Bridgewater, NJ 08807
US
Bridgewater, NJ 08807
US
908 809 1300
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc operates as a specialized drug company, dedicated to innovating and marketing pharmaceutical solutions for patient groups with unmet needs in the ophthalmic and medical aesthetics domains. The firm's activities extend across the United States, Argentina, and Hungary. Its principal commercial offering is Upneeq (RVL-1201), an ophthalmic solution containing oxymetazoline hydrochloride, specifically formulated to address acquired blepharoptosis, or drooping eyelids, in adults. The company, formerly known as Osmotica Pharmaceuticals plc, officially rebranded to RVL Pharmaceuticals plc in January 2022. Its corporate headquarters are situated in Bridgewater, New Jersey.
Latest News
No recent news
Recent Insider Trades
No insider trades found